Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $27000.0.

  • Utah Medical Products' Capital Expenditures fell 6966.29% to $27000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $271000.0, marking a year-over-year decrease of 1286.17%. This contributed to the annual value of $230000.0 for FY2024, which is 6400.63% down from last year.
  • As of Q3 2025, Utah Medical Products' Capital Expenditures stood at $27000.0, which was down 6966.29% from $51000.0 recorded in Q2 2025.
  • In the past 5 years, Utah Medical Products' Capital Expenditures ranged from a high of $321000.0 in Q3 2022 and a low of $9000.0 during Q4 2024
  • Over the past 5 years, Utah Medical Products' median Capital Expenditures value was $90000.0 (recorded in 2023), while the average stood at $131157.9.
  • Its Capital Expenditures has fluctuated over the past 5 years, first tumbled by 9779.74% in 2021, then surged by 227000.0% in 2022.
  • Utah Medical Products' Capital Expenditures (Quarter) stood at $253000.0 in 2021, then crashed by 84.98% to $38000.0 in 2022, then soared by 136.84% to $90000.0 in 2023, then crashed by 90.0% to $9000.0 in 2024, then surged by 200.0% to $27000.0 in 2025.
  • Its last three reported values are $27000.0 in Q3 2025, $51000.0 for Q2 2025, and $184000.0 during Q1 2025.